FLVCR2 and lung adenocarcinoma: As a critical submit of the CCT complex, CCT6A plays a carcinogenic role in various malignancies.[38, 39, 40, 41] For example, CCT6A promotes tumor progression in lung adenocarcinoma through the STAT1/HK2 axis,[41] and facilitates metastasis in non‐small‐cell lung carcinoma by competitively binding to SMAD2.[39] In CRC, it has been reported that CCT6A is highly expressed in tumor tissues and serves as a predictor of poor prognosis.[42] Silencing CCT6A can effectively inhibit the proliferation, invasion, and metastasis of CRC cells.[43] These results are coincident with our study.